{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:46:50Z","timestamp":1790941610915,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":40,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007791.pub3","type":"reference-entry","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T19:52:45Z","timestamp":1334260365000},"source":"Crossref","is-referenced-by-count":20,"title":["Antioxidants and other pharmacological treatments for Friedreich ataxia"],"prefix":"10.1002","author":[{"given":"Mary","family":"Kearney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,18]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD007791.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1212\/01.WNL.0000055872.50364.FC","article-title":"Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial","volume":"60","author":"Mariotti","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Prospero","year":"2007","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD007791.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007791.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-004-0216-x","article-title":"L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial","volume":"112(6)","author":"Sch\u00f6ls","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007791.pub3-BIB7|cit7","unstructured":"NCT00530127 A study investigating the safety and tolerability of deferiprone in patients with Friedreich's ataxia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00530127"},{"key":"10.1002\/14651858.CD007791.pub3-BIB8|cit8","unstructured":"NCT 00811681 Effect of pioglitazone administered to patients with Friedreich's ataxia: proof of concept (ACTFRIE) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00811681"},{"key":"10.1002\/14651858.CD007791.pub3-BIB9|cit9","unstructured":"NCT00824512 Efficacy of EGb761 in patients suffering from Friedreich ataxia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00824512"},{"key":"10.1002\/14651858.CD007791.pub3-BIB10|cit10","unstructured":"NCT01016366 Safety study of carbamylated erythropoetin to treat patients with the neurodegenerative disorder Friedreich's ataxia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01016366"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007791.pub3-BIB11|cit11","first-page":"S153","article-title":"12 month European phase III clinical study of SNT-MC17\/ idebenone in the treatment of Friedreich's ataxia: baseline neurology data and interim safety results","volume":"256","author":"Schultz","year":"2009","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2002-34494","article-title":"Friedreich's ataxia: idebenone treatment in early stage patients","volume":"33","author":"Artuch","year":"2002","journal-title":"Neuropediatrics"},{"key":"10.1002\/14651858.CD007791.pub3-BIB13|cit13","unstructured":"Ataxia UK Developing stem cell therapies for Friedreich\u2019s ataxia http:\/\/www.ataxia.org.uk\/data\/files\/summary_for_webwilkins_stemcells_for_fa_15_12_08__corrected.pdf"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biological and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007791.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich's ataxia; clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub3-BIB16|cit16","first-page":"1569","article-title":"Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring","volume":"60","author":"Buyse","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/mds.22660","article-title":"Comparison of three clinical rating scales in Friedreich Ataxia (FRDA)","volume":"24","author":"B\u00fcrk","year":"2009","journal-title":"Movement Disorders"},{"issue":"5254","key":"10.1002\/14651858.CD007791.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's Ataxia: Autosomal Recessive Disease caused by an Intronic GAA Triplet Repeat Expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1002\/14651858.CD007791.pub3-BIB19|cit19","series-title":"European Federation of Neurological Societies Conference","author":"Christou","year":"2010"},{"key":"10.1002\/14651858.CD007791.pub3-BIB20|cit20","unstructured":"European Medicines Agency Sovrima: EPAR - Public assessment report. EMEA\/387246\/2009 http:\/\/www.ema.europa.eu"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.55.11.1752","article-title":"Increased levels of plasma malondialdehyde in Friedreich ataxia","volume":"55","author":"Emond","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub3-BIB22|cit22","unstructured":"euro-ATAXIA newsletter no. 34 www.euro-ataxia.eu\/newsletter\/eanews34.pdf"},{"key":"10.1002\/14651858.CD007791.pub3-BIB23|cit23","doi-asserted-by":"crossref","unstructured":"Gimenez-Cassina A Wade-Martins R Gomez-Sebastian S Corona JC Lim F D\u00edaz-Nido J Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector Gene Therapy 2011","DOI":"10.1038\/gt.2011.45"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"American Journal Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia","volume":"87","author":"Hausse","year":"2002","journal-title":"Heart"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nature Chemical Biology"},{"key":"10.1002\/14651858.CD007791.pub3-BIB27|cit27","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"13","key":"10.1002\/14651858.CD007791.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1182\/blood-2008-06-161919","article-title":"Cell function impaired by frataxin deficiency are restored by drug-mediated iron chelation","volume":"112","author":"Kakhlon","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","article-title":"Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study","volume":"52","author":"Lodi","year":"2001","journal-title":"Cardiovascular Research"},{"key":"10.1002\/14651858.CD007791.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/mds.20449","article-title":"Performance measures in Friedreich ataxia: potential utility as clinical outcome tools","volume":"20 (7)","author":"Lynch","year":"2005","journal-title":"Movement Disorders"},{"issue":"s3","key":"10.1002\/14651858.CD007791.pub3-BIB31|cit31","first-page":"598","article-title":"Erythropoietin in patients with Friedreich's ataxia: results of a randomized, double-blind, placebo controlled, dose-finding clinical trial","volume":"17","author":"Mariotti","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD007791.pub3-BIB32|cit32","article-title":"Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease","author":"Orrell","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007791.pub3-BIB33|cit33","series-title":"American Academy of Neurology Conference 2010 Apr 10-17. Available from http:\/\/www.mindcull.com\/abstract:cb7b7b13da2856dacd22e217f78f42a3\/","article-title":"Development of biomarkers for HDAC inhibitor treatment of Friedreich's ataxia.","author":"Pandolfo"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-2094-1-3","article-title":"Effect of pioglitazone treatment in a patient with secondary multiple sclerosis","volume":"1","author":"Pershadsingh","year":"2004","journal-title":"Journal of Neuroinflammation"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejpn.2007.11.006","article-title":"Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up","volume":"12","author":"Pineda","year":"2008","journal-title":"European Journal of Paediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archneur.64.4.558","article-title":"Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up","volume":"64","author":"Ribai","year":"2007","journal-title":"Archives of Neurology"},{"issue":"9177","key":"10.1002\/14651858.CD007791.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(99)01341-0","article-title":"Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study","volume":"354","author":"Rustin","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007791.pub3-BIB38|cit38","unstructured":"Santhera May 20, 2010: Santhera's MICONOS Trial with Catena\u00ae\/Sovrima\u00ae in Friedreich's Ataxia Misses Primary Endpoint [press release] http:\/\/www.santhera.com"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub3-BIB40|cit40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007791.pub2","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","author":"Kearney","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007791.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007791.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:13:49Z","timestamp":1628547229000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007791.pub3"}},"subtitle":[],"editor":[{"given":"Mary","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,18]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007791.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007791.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,4,18]]}}}